NRx Pharmaceuticals Reports Second Quarter 2023 Financial Re

Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and...

Related Keywords

United States , Americans , Stephen Willard , Lotus , Us Department Of Defense , Source Nrx Pharmaceuticals Inc , Research Program , Northwestern University Feinberg School Of Medicine , Nrx Pharmaceuticals , Northwestern University , Nrxp Nrx Pharmaceuticals , International Journal Of Bipolar Disorders , Contract Research Organization , Nrx Pharmaceuticals Inc , Nasdaq , Neuroscience Institute , Lotus Pharmaceuticals , Alvogen Pharmaceuticals , International Journal , Bipolar Disorders , Investigational New Drug , Chief Executive Officer , Mortality Weekly , Chronic Pain , Quarter Clinical , Bipolar Depression , Fast Track Designation , Breakthrough Therapy Designation , Special Protocol Agreement , Biomarker Letter , Severe Bipolar Depression , Acute Suicidal , Data Safety Monitoring Board , Vania Apkarian , Northwestern University Feinberg School , Scientific Advisory , Pain Pathway , Congressionally Directed Medical Research , Post Traumatic Stress Disorder , Streeterville Capital , Second Quarter Ended June , Suicidal Treatment Resistant Bipolar Depression , Securities Litigation Reform Act , Earnout Cash ,